The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Elisa A. Rozeman
Travel, Accommodations, Expenses - MSD; NanoString Technologies
 
Rodabe Navroze Amaria
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Alexander Chan Chi Huang
No Relationships to Disclose
 
Richard A. Scolyer
No Relationships to Disclose
 
Michael T. Tetzlaff
Consulting or Advisory Role - Myriad Genetics; Novartis
 
Bart A. Van De Wiel
No Relationships to Disclose
 
Serigne Lo
No Relationships to Disclose
 
Ahmad A. Tarhini
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Incyte; Merck; Newlink Genetics; Novartis; OncoSec
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GreenPeptide (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Prometheus (Inst); Prometheus (Inst)
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)
 
Elizabeth M. Burton
No Relationships to Disclose
 
Giorgos Karakousis
No Relationships to Disclose
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; MedImmune; Merck Serono; Merck Sharp & Dohme; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Andrew Spillane
No Relationships to Disclose
 
Michael A. Davies
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; NanoString Technologies; Novartis; Sanofi; Syndax; Vaccinex
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst)
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Tara C. Mitchell
Consulting or Advisory Role - Aduro Biotech; Bristol-Myers Squibb; Incyte; Merck; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Roche (Inst)
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre
Research Funding - BMS Brazil (Inst); Merck (Inst)
 
Jennifer Ann Wargo
Leadership - Microbiome DX
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Dava Oncology; Genentech; Gilead Sciences; GlaxoSmithKline; Illumina; Merck; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Illumina; Merck; Novartis
Speakers' Bureau - Dava Oncology; Genentech; Illumina; Novartis; PER; Precision Health Economics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent submitted regarding the role of the microbiome in response to immune checkpoint blockade
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; Genentech; GlaxoSmithKline; Illumina; Novartis
 
Christian U. Blank
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb